RT Journal Article
SR Electronic
T1 Prioritizing disease-causing metabolic genes by integrating metabolomics with whole exome sequencing data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.21.21257573
DO 10.1101/2021.05.21.21257573
A1 Bongaerts, Michiel
A1 Bonte, Ramon
A1 Demirdas, Serwet
A1 Huidekoper, Hidde
A1 Langendonk, Janneke
A1 Wilke, Martina
A1 de Valk, Walter
A1 Blom, Henk J.
A1 Reinders, Marcel J.T.
A1 Ruijter, George J. G.
YR 2021
UL http://medrxiv.org/content/early/2021/05/24/2021.05.21.21257573.abstract
AB The integration of metabolomics data with sequencing data is a key step towards improving the diagnostic process for finding the disease-causing gene(s) in patients suspected of having an inborn error of metabolism (IEM). The measured metabolite levels could provide additional phenotypical evidence to elucidate the degree of pathogenicity for variants found in metabolic genes. We present a computational approach, called Reafect, that calculates for each reaction in a metabolic pathway a score indicating whether that reaction is being deficient or not. When calculating this score, Reafect takes multiple factors into account: the magnitude and sign of alterations in the metabolite levels, the reaction distances between metabolites and reactions in the pathway, and the biochemical directionality of the reactions. We applied Reafect to untargeted metabolomics data of 72 patient samples with a known IEM and found that in 80% of the cases the correct deficient enzyme was ranked within the top 5% of all considered enzyme deficiencies. Next, we integrated Reafect with CADD scores (a measure for variant deleteriousness) and ranked the potential disease-causing genes of 27 IEM patients. We observed that this integrated approach significantly improved the prioritization of the disease-causing genes when compared with the two approaches individually. For 15/27 IEM patients the correct disease-causing gene was ranked within the top 0.2% of the set of potential disease-causing genes. Together, our findings suggest that metabolomics data improves the identification of disease-causing genetic variants in patients suffering from IEM.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Erasmus Medical Centre, department of Clinical Genetics. No external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Erasmus MC review board has provided exemption for the current investigation in a letter dated March 30, 2018, in line with applicable Dutch law and guidelines.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available on request. Software is available. https://github.com/mbongaerts/Reafect